Mounjaro 2.5 mg/0.5 mL pre-filled single-dose pen ( Japan Version) 2 dose per box

### **Mounjaro (Japan Version) – 2.5 mg/0.5 mL Pre-filled Single-dose Pen (2 Doses per Box)**

**Overview**:
Mounjaro, containing the active ingredient **tirzepatide**, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily used to improve blood sugar control in adults with type 2 diabetes. The **2.5 mg/0.5 mL pre-filled pen** is generally used as a **starting dose** to help patients adjust to the medication before transitioning to higher doses. The Japan-specific version adheres to local standards for packaging and instructions.

**Dosage**:
– **2.5 mg/0.5 mL** is the initial, introductory dose of Mounjaro, used for new patients starting tirzepatide therapy. After 4 weeks on the 2.5 mg dose, patients usually progress to higher doses, such as 5 mg or 7.5 mg, depending on the treatment plan and patient response.
– **2 doses per box**: Each box contains two single-dose pre-filled pens, with each pen delivering one 2.5 mg dose of tirzepatide.

**Key Features**:
– **Dual Mechanism of Action**: Tirzepatide targets both GIP and GLP-1 receptors, which enhances insulin secretion, reduces glucagon release, and slows gastric emptying. This dual action offers a more comprehensive glycemic control than single GLP-1 receptor agonists.
– **Once Weekly Injection**: The 2.5 mg dose is injected subcutaneously once a week, ensuring convenience for patients.
– **Pre-filled Pen**: The pen is designed for easy use, ideal for patients who need to self-administer their medication. It requires no preparation and delivers the full dose with a single injection.

**Indications**:
– **Type 2 Diabetes**: Mounjaro is prescribed to manage blood sugar levels in adults with type 2 diabetes, often in combination with other diabetes treatments such as metformin or insulin.
– **Introductory Dose**: The 2.5 mg dose serves as an introductory dose to help patients become accustomed to the effects of tirzepatide before increasing to a higher maintenance dose.

**Usage and Administration**:
– **Frequency**: The 2.5 mg dose is administered once weekly, on the same day each week. It can be taken with or without food.
– **Dose Adjustment**: After starting on the 2.5 mg dose for at least 4 weeks, most patients will move to the 5 mg dose or higher for ongoing blood sugar control. The 2.5 mg dose is not intended for long-term maintenance.

**Storage**:
– **Before Use**: Store the Mounjaro pens in a refrigerator (2°C to 8°C) before use. Do not freeze the medication.
– **After Use**: Once the pen is taken out of the refrigerator, it can be stored at room temperature (below 30°C) for up to 21 days.

**Japan-specific Packaging**:
– **2 Doses per Box**: The Japanese version comes with two 2.5 mg pre-filled pens, offering a two-week supply of the starting dose.
– The packaging and labeling are designed in accordance with Japan’s regulatory requirements, but the medication and its effects are consistent with global standards.

**Conclusion**:
Mounjaro (tirzepatide) 2.5 mg/0.5 mL pre-filled pen serves as an important starting dose for patients newly beginning tirzepatide therapy. It helps the body adjust to the medication’s effects before moving to higher doses. The pre-filled, once-weekly pen is convenient and easy to use, making it a user-friendly option for individuals managing type 2 diabetes.